Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies

INTRODUCTION: Diabetes mellitus (DM) carries an elevated risk for cardiovascular disease. Here, we assessed alirocumab efficacy and safety in people with/without DM from five placebo-controlled phase 3 studies. METHODS: Data from up to 78 weeks were analyzed in individuals on maximally tolerated bac...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Ther
Asıl Yazarlar: Ginsberg, Henry N., Farnier, Michel, Robinson, Jennifer G., Cannon, Christopher P., Sattar, Naveed, Baccara-Dinet, Marie T., Letierce, Alexia, Bujas-Bobanovic, Maja, Louie, Michael J., Colhoun, Helen M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984942/
https://ncbi.nlm.nih.gov/pubmed/29779195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0439-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller